Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results

Post Views: 87 Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization, today announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021. John Rim, CEO of Samsung Biologics, stated, “With a steep increase in demand for medicines due to the prolonged COVID-19 pandemic, there…